Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

10.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,942
Open 10.20
Bid (Size) 10.14 (2)
Ask (Size) 10.18 (2)
Prev. Close 10.20
Today's Range 10.20 - 10.20
52wk Range 7.400 - 11.45
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+7.03%
+7.03%
1 Month
+3.66%
+3.66%
3 Month
+36.36%
+36.36%
6 Month
+11.84%
+11.84%
1 Year
+23.94%
+23.94%

More News

Read More
Migraine Medication Battle: Eli Lilly Prevails in Patent Infringement Case Against Teva
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise
Via Investor's Business Daily
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Via Benzinga
3 No-Brainer Stocks to Buy With $20 Right Now
Via The Motley Fool
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
Via Benzinga
TEVA - A Pharma Stock To Watch
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
Via Benzinga
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
S&P Slashes Ratings Of Five US Banks, SEC Fines Fintech Adviser Titan For Misleading Crypto Claims, Microsoft Modifies Activision Blizzard Purchase: Today's Top Stories
Via Benzinga
Topics Regulatory Compliance Stocks
Exposures Legal Regulatory US Equities
Big Pharma Price-Fixing: Teva and Glenmark's $255M Settlement Shines Light on Industry Issues
Via Benzinga
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
Via Benzinga
Exposures Product Safety
Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Teva Pharmaceutical, Marathon Oil And 2 Other Stocks Insiders Are Selling
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo
Via Benzinga
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.